The EDEM3 Knockout MES-OV Polyclonal Cells product comprises a population of human MES-OV ovarian carcinoma cells subjected to CRISPR/Cas9-mediated disruption of the EDEM3 gene, generating a mixed polyclonal knockout model for studying endoplasmic reticulum (ER)-associated degradation (ERAD) and the unfolded protein response (UPR). This polyclonal format obviates clonal biases, providing a representative loss-of-function model that preserves the heterogeneous signaling landscape typical of cancer cell populations, thereby facilitating robust functional studies of glycoprotein quality control in an ovarian carcinoma background.
The MES-OV parental line is a well-established human ovarian carcinoma cell line that faithfully models ovarian tumorigenesis and metastatic progression. Exhibiting epithelial morphology and relevant oncogenic alterations, MES-OV cells are widely employed to dissect molecular mechanisms driving ovarian cancer, including ER stress adaptation, metabolic reprogramming, and drug sensitivity. This host cell background offers a clinically pertinent system in which to interrogate the contributions of EDEM3 to protein homeostasis and tumor cell survival under proteotoxic stress, a hallmark of high-grade serous ovarian carcinoma.
EDEM3 encodes an ER-resident alpha-1,2-mannosidase that specifically trims terminal mannose residues from N-glycans on misfolded glycoproteins, a critical step that targets these substrates for SEL1L-HRD1 E3 ligase-mediated ubiquitination and subsequent dislocation into the cytosol for proteasomal degradation. EDEM3 functions within the ERAD network, interacting with lectins OS9 and XTP3-B, the retrotranslocation channel, and the p97/VCP ATPase complex. EDEM3 expression is transcriptionally regulated by the unfolded protein response (UPR) sensors ATF6 and XBP1, and its activity is coordinated with homologs EDEM1 and EDEM2 to ensure efficient clearance of aberrant glycoproteins. In the absence of EDEM3, misfolded glycoproteins accumulate, triggering sustained UPR signaling via ATF6, IRE1??/XBP1, and PERK/ATF4 arms, which can lead to apoptosis if unresolved.
Disruption of EDEM3 in MES-OV cells creates a model system in which ERAD-mediated protein quality control is compromised, leading to constitutive or aggravated ER stress. This polyclonal knockout population allows researchers to explore how ovarian carcinoma cells adapt to the resultant accumulation of misfolded glycoproteins and sustained UPR signaling, processes tightly linked to tumorigenesis, chemoresistance, and immune evasion. The interplay between EDEM3 loss and the SEL1L-HRD1 complex, OS9/XTP3-B substrate recognition, and p97/VCP-dependent extraction can be interrogated to dissect pro-survival versus pro-apoptotic outcomes, providing a versatile platform to study the role of glycoprotein quality control in ovarian cancer pathogenesis and therapy response.
Typical applications include western blotting for EDEM3 and UPR markers (BiP, CHOP), RT-qPCR profiling of UPR target genes, immunofluorescence microscopy to assess ER morphology, flow cytometry for apoptosis, and cell viability assays under ER stress inducers such as tunicamycin and thapsigargin. These polyclonal knockout cells are particularly suited for investigating ER stress responses in ovarian cancer, functional analysis of N-glycan processing in tumorigenesis, drug resistance screening, and dissecting the crosstalk between ERAD and oncogenic signaling. For further technical details, please reach out to Ascent Research.
